Display options
Cite
Haraoui B, Jamal S, Ahluwalia V, et al. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatol Ther. 2018;5(2):551-565doi: 10.1007/s40744-018-0130-6.
Haraoui, B., Jamal, S., Ahluwalia, V., Fung, D., Manchanda, T., & Khraishi, M. (2018). Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatology and therapy, 5(2), 551-565. https://doi.org/10.1007/s40744-018-0130-6
Haraoui, Boulos, et al. "Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study." Rheumatology and therapy vol. 5,2 (2018): 551-565. doi: https://doi.org/10.1007/s40744-018-0130-6
Haraoui B, Jamal S, Ahluwalia V, Fung D, Manchanda T, Khraishi M. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28. PMID: 30370468; PMCID: PMC6251854.
Copy Download .nbib Format: NLM
Share it on

Rheumatol Ther. 2018 Dec;5(2):551-565. doi: 10.1007/s40744-018-0130-6. Epub 2018 Oct 28.

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study.

Rheumatology and therapy

Boulos Haraoui, Shahin Jamal, Vandana Ahluwalia, Diana Fung, Tarang Manchanda, Majed Khraishi

Affiliations

  1. Department of Medicine, Université de Montréal, Montreal, QC, Canada. [email protected].
  2. Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  3. Rheumatology Division, William Osler Health System, Brampton, ON, Canada.
  4. Hoffmann-La Roche Canada, Mississauga, ON, Canada.
  5. Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.

PMID: 30370468 PMCID: PMC6251854 DOI: 10.1007/s40744-018-0130-6

Abstract

INTRODUCTION: This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).

METHODS: This was a 12-month noninterventional, observational study in adult patients with RA who initiated tocilizumab in routine practice in Canada according to the local product monograph. The primary end point was the proportion of patients receiving tocilizumab at 6 months. Secondary end points were treatment patterns, effectiveness, and safety of tocilizumab over 12 months.

RESULTS: Of 200 patients who initiated tocilizumab (91.0% at 8 mg/kg), 67 (33.5%) received tocilizumab monotherapy and 133 (66.5%) received tocilizumab combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Kaplan-Meier analysis estimated that 85% (95% CI 74-92%) of monotherapy and 89% (95% CI 82-93%) of combination therapy patients continued to receive tocilizumab at 6 months (log-rank p = 0.0888). During the observation period, 12 (17.9%) monotherapy and 27 (20.3%) combination therapy patients withdrew from the study. At month 12, 58.5% in the monotherapy group and 59.3% in the combination therapy group achieved Disease Activity Score at 28 joints remission (≤ 2.6), 25.6% and 24.7% achieved Simplified Disease Activity Index remission (≤ 3.3), and 18.2% and 22.3% achieved Clinical Disease Activity Index remission (≤ 2.8), respectively. Rates of serious adverse events and serious infections were found in 29.6/100 patient-years (PY) and 3.1/100 PY, respectively, for monotherapy and 19.2/100 PY and 4.8/100 PY, respectively, for combination therapy.

CONCLUSIONS: Patients initiating tocilizumab in routine practice had comparable effectiveness and safety outcomes regardless of whether they received tocilizumab as monotherapy or as combination therapy with csDMARDs.

TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01613378 FUNDING: F. Hoffmann-La Roche (Roche) Canada.

Keywords: Antirheumatic agents; Biological agents; Inflammation; Interleukin-6 receptor; Primary care; Rheumatoid arthritis; Tocilizumab

References

  1. Arthritis Rheum. 2008 Oct;58(10):2968-80 - PubMed
  2. Int Immunopharmacol. 2005 Nov;5(12):1731-40 - PubMed
  3. Ann Rheum Dis. 2012 Dec;71(12):1950-4 - PubMed
  4. Ann Rheum Dis. 2016 Jun;75(6):1081-91 - PubMed
  5. Lancet. 2008 Mar 22;371(9617):987-97 - PubMed
  6. J Rheumatol. 2012 Aug;39(8):1559-82 - PubMed
  7. Blood. 2008 Nov 15;112(10):3959-64 - PubMed
  8. Clin Exp Rheumatol. 2017 Nov-Dec;35(6):899-906 - PubMed
  9. Expert Opin Biol Ther. 2010 Sep;10(9):1367-78 - PubMed
  10. Lancet. 2013 May 4;381(9877):1541-50 - PubMed
  11. Ann Rheum Dis. 2014 Mar;73(3):492-509 - PubMed
  12. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39 - PubMed
  13. Ann Rheum Dis. 2016 Jan;75(1):3-15 - PubMed
  14. Clin Rheumatol. 2015 Mar;34(3):563-71 - PubMed
  15. Ann Rheum Dis. 2013 Jan;72(1):43-50 - PubMed
  16. Ann Rheum Dis. 2008 Nov;67(11):1516-23 - PubMed
  17. Ann Rheum Dis. 2010 Jan;69(1):88-96 - PubMed
  18. Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71 - PubMed
  19. Ann Rheum Dis. 2011 Apr;70(4):583-9 - PubMed
  20. Arthritis Rheum. 2011 Mar;63(3):609-21 - PubMed
  21. J Rheumatol. 2013 Jun;40(6):768-80 - PubMed
  22. J Rheumatol. 2009 Aug;36(8):1611-7 - PubMed
  23. Bull NYU Hosp Jt Dis. 2008;66(2):77-85 - PubMed

Publication Types